The Gap Nobody Warns You About After I-Corps
You validated the problem. You have customer interviews. Now you have to actually build a regulated company — and that's where most medtech founders stall.
I-Corps does one thing exceptionally well: it teaches you that your first idea about who needs your product is probably wrong. You do the interviews, you kill your assumptions, and you come out the other side with a problem you can actually defend.
Then the program ends, and the real gap opens up.
Validation is not execution
Knowing that a problem is worth solving doesn’t tell you how to build the thing that solves it inside a regulated industry. For medtech founders, the post-I-Corps moment looks like this: you have a validated pain point, a stack of customer quotes, and absolutely no idea whether your device is a 510(k), a De Novo, or a PMA — or what any of those mean for your timeline and your next grant.
That’s the gap. Not the idea. The execution.
Where founders actually stall
A few patterns show up over and over:
- Regulatory paralysis. The founder treats the FDA pathway as a problem for “after the science works,” then a grant deadline arrives and there’s no regulatory strategy to write.
- Consultant sticker shock. The first quote for a regulatory assessment comes back at five figures and weeks of turnaround — neither of which a pre-revenue founder has.
- Vocabulary gaps that cost credibility. Writing “FDA approval” for a device that needs clearance tells a reviewer you haven’t done the work, even when you have.
None of these are problems of motivation or intelligence. They’re problems of not having done this specific thing before — which is exactly the thing I-Corps doesn’t cover.
Closing it
The fix isn’t another accelerator. It’s getting the concrete artifacts in hand early: your device classification, a likely pathway, a representative predicate, and the testing categories that pathway implies. Do that work once and it feeds your grant, your investor conversations, and your build plan all at once.
The founders who break through aren’t the ones with the best idea. They’re the ones who turned a validated problem into a regulated, fundable plan before the momentum from I-Corps wore off.
That’s the whole reason RegReady exists — to hand you those artifacts in minutes instead of weeks, so the execution gap doesn’t swallow your timeline.